Media and Communications

News

2001 News Releases

Monday, December 17, 2001
Teva Announces Final Approval of Lovastatin Tablets

FEDERAL JUDGE INVALIDATES AN AUGMENTIN PATENT Jerusalem, Israel, December 17, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has received final FDA approval of its Abbreviated New Drug Application (ANDA) for Lovastatin Tablets 10, 20 and 40 mg, following the expiration of Merck's period of pediatric exclusivity for Mevacor. Teva had originally received approval in June 2001, but the FDA subsequently awarded six months pediatric exclusivity to Merck. Annual sales of Mevacor are estimated at approximately $200 million, and Teva will launch its Lovastatin table Read More »

Tuesday, December 04, 2001
Teva and Proneuron Biotechnologies Entered into an Agreement to Develop glatiramer acetate for Multiple Neurodegenerative Diseases

New uses of glatiramer acetate - the active ingredient of Copaxone® - as a potential neuroprotective agent to be developed under this agreement Jerusalem, Israel, December 4, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), today announced that Teva and Proneuron Biotechnologies Inc., entered into a strategic alliance agreement that includes the potential development and exclusive commercialization of glatiramer acetate for diseases which may be treatable with a neuroprotective agent. These include Alzheimer's Disease, stroke, brain trauma, glaucoma, Parkinson's Disease, peripheral Read More »

Wednesday, November 14, 2001
Teva not Acquiring Faulding Injectable Business

Jerusalem, Israel, November 14, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), today announced that following its initial due diligence review, Teva has decided not to acquire the Faulding injectable business from Mayne Nickless Limited.Eli Hurvitz, President and CEO, stated: "We were quite disappointed with the findings of our due diligence which together with other unresolved issues, determined that the acquisition would not be justified under our usual stringent standards, and therefore decided not to pursue our option. We believe that our existing injectable business in Eu Read More »

Tuesday, October 23, 2001
Teva to Announce Third Quarter Earnings

Jerusalem, Israel, October 23, 2001 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) today announced it will release its third quarter financial results on Wednesday, October 31, 2001.The Company will host a conference call to be webcast on October 31 at 10:00 a.m. EST to discuss the financial results. To access the live webcast, go to Teva's web site at www.tevapharm.com and click on the conference call icon. Please login at least 10 minutes prior to the conference call in order to download the applicable audio software should you require it. A replay of the webcast will be available withi Read More »

Wednesday, October 10, 2001
Teva Announces that Health Canada Has Approved Enhanced Labeling for Copaxone®

Jerusalem, Israel, October 10, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that Health Canada has approved enhanced labeling for its multiple sclerosis drug COPAXONE® (glatiramer acetate for injection). The new label reflects the positive result of a large multicenter, double-blind, placebo-controlled study that showed a significant reduction of MRI gadolinium-enhancing lesions (new active lesions) in patients treated with COPAXONE®. Physicians increasingly use MRI for their diagnosis and treatment of MS.Treatment with COPAXONE® showed a significant reduction in T Read More »

Monday, October 01, 2001
Teva's Copaxone® Shown to Reduce "Black Holes" in the Brain

KANSAS City, Mo. and Jerusalem, Israel, October 1, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that a study published in the August issue of Neurology showed that COPAXONE® (glatiramer acetate for injection) reduced by 50% the percentage of permanent "black holes" that developed in patients with relapsing-remitting multiple sclerosis. Black holes are lesions MS can cause in the brain, and these lesions, if permanent, represent areas where the most severe and irreversible brain tissue damage has occurred."This study was designed to determine if glati Read More »

Wednesday, September 19, 2001
Teva Announces Approval of Enalapril / HCTZ Tablets

Jerusalem, Israel, September 19, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration (FDA) has issued final approval for the company's ANDA for ENALAPRIL MALEATE / HYDROCHLOROTHIAZIDE TABLETS.ENALAPRIL MALEATE / HYDROCHLOROTHIAZIDE TABLETS are the generic equivalent of Merck's antihypertensive drug Vaseretic. The brand product had 2000 sales of approximately $57 million. Teva plans to launch immediatelyTeva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 40 pharmaceutical companies and among the largest Read More »

Wednesday, September 19, 2001
Teva Announces Approval of Flutamide Capsules

Jerusalem, Israel, September 19, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration (FDA) has issued final approval for the Company's ANDA for Flutamide Capsules.Flutamide Capsules are the generic equivalent of Schering Corp's antineoplastic drug, Eulexin Capsules. The brand product had 2000 sales of approximately $48 million. Teva plans to launch immediately.Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 40 pharmaceutical companies and among the largest generic pharmaceutical companies in the wo Read More »

Friday, September 14, 2001
Teva Pharmaceutical Industries Announce Interim Results of Coral Study

Jerusalem, September 14, 2001 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that an interim analysis of its Coral (oral Copaxone) trial showed a trend for a treatment effect in favor of the higher oral dose in patients who were treated for more than a year, although the difference has not reached statistical significance. The independent Data Safety Monitoring Committee (DSMC) that has been monitoring the trial has recommended continuing the trial to its completion by October 2001. As previously reported by Teva, the oral formulation could not be available for commercial Read More »

Wednesday, August 15, 2001
Teva to Hold Conference Call on Wednesday, August 15, 2001

Management To Review Recent Corporate Announcements Jerusalem, Israel, August 15, 2001 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) announced it will host a conference call today, August 15, 2001, at 10:30 AM EST to review the Company's recent corporate announcments.To access the live webcast, go to Teva's web site at www.tevapharm.com and click on the conference call icon. Please login at least 10 minutes prior to the conference call in order to download the applicable audio software. A replay of the webcast will be available within 24 hours at the Company's website. Alternatively, a Read More »

​​​